The Duke Cancer Institute (DCI) wants to assure our patients that the safety of our patients, their loved ones, our team members and the community at large remains our highest priority. We are closely monitoring this rapidly evolving situation and are implementing all necessary precautions to prevent the spread of infection.

For the latest information about how we are keeping our community safe, please visit www.dukehealth.org.

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab with VEGF TKI cabozantinib in metastatic untreated REnal Cell CancEr (Alliance A031704)

2020 PDIGREE ASCO

Contact

For more information on this presentation, please contact:

Tian Zhang, MD, MHS
Twitter: @TiansterZhang
Email: Tian Zhang